Catawba Capital Management’s Novartis NVS Stock Holding History

Catawba Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$2.03M	Sell	30,056 -529	-2%	-$36.5K	0.48%	66
2018 Q1	$2.22M	Sell	30,585 -2,123	-6%	-$162K	0.53%	62
2017 Q4	$2.46M	Sell	32,708 -2,081	-6%	-$157K	0.56%	60
2017 Q3	$2.68M	Buy	34,789 +843	+2%	+$63.7K	0.6%	56
2017 Q2	$2.54M	Buy	33,946 +1,925	+6%	+$136K	0.58%	62
2017 Q1	$2.13M	Buy	32,021 +603	+2%	+$40.2K	0.46%	67
2016 Q4	$2.05M	Sell	31,418 -589	-2%	-$38.2K	0.48%	65
2016 Q3	$2.27M	Sell	32,007 -1,630	-5%	-$119K	0.54%	61
2016 Q2	$2.49M	Buy	33,637 +273	+0.8%	+$18.9K	0.6%	56
2016 Q1	$2.17M	Buy	33,364 +78	+0.2%	+$5.31K	0.55%	59
2015 Q4	$2.57M	Buy	33,286 +391	+1%	+$31.1K	0.7%	49
2015 Q3	$2.71M	Sell	32,895 -486	-1%	-$43.3K	0.74%	47
2015 Q2	$2.94M	Sell	33,381 -507	-1%	-$46.5K	0.7%	49
2015 Q1	$2.99M	Buy	33,888 +1,082	+3%	+$96K	0.69%	50
2014 Q4	$2.72M	Hold	32,806	–	–	0.63%	53
2014 Q3	$2.77M	Buy	32,806 +140	+0.4%	+$11.3K	0.64%	59
2014 Q2	$2.65M	Buy	32,666 +223	+0.7%	+$17.5K	0.6%	62
2014 Q1	$2.47M	Hold	32,443	–	–	0.59%	65
2013 Q4	$2.34M	Buy	32,443 +2,137	+7%	+$149K	0.56%	65
2013 Q3	$2.08M	Buy	30,306 +210	+0.7%	+$13.9K	0.55%	67
2013 Q2	$1.91M	Buy	+30,096	New	+$1.96M	0.53%	68

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Catawba Capital Management's NVS Position: Q2 2018 in Review

Catawba Capital Management reduced its Novartis (NVS) stake by 1.7% in Q2 2018, selling an estimated $36.5K and leaving 30,056 shares worth $2.03M. The position accounts for 0.48% of the portfolio, ranked #66.

Catawba Capital Management first reported a position in NVS in Q2 2013 and has held it in 21 quarters since. The position peaked at $2.99M in Q1 2015. 987 funds tracked by Wall St. Rank hold NVS as of Q2 2018.

Catawba Capital Management held 30,056 shares of Novartis worth $2.03M as of Q2 2018.
Catawba Capital Management sold 529 Novartis shares in Q2 2018, an estimated $36.5K.
Novartis made up 0.48% of Catawba Capital Management's portfolio in Q2 2018, its #66 holding.
Catawba Capital Management first reported a position in Novartis in Q2 2013 and has held it in 21 quarters since.
Catawba Capital Management's Novartis position peaked at $2.99M in Q1 2015.
987 funds tracked by Wall St. Rank held Novartis as of Q2 2018.

Based on Catawba Capital Management's 13F filing for Q2 2018, filed 11 Jul 2018.